Clinical and prognostic role of the plasma level of stimulating growth factor in patients with miscellaneous cardiovascular pathology
Aim. To determine the clinical and prognostic role of plasma level of stimulating growth factor inmiscellaneouscardiovascular pathology. Material and Methods. There was carried out a review of literature highlighting the clinical and prognostic role of the plasma level of the stimulating growth f...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN UK |
| Publicado: |
Danylo Halytsky Lviv National Medical University
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/719e2dee43f04bcaa2962aefd35e225c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Aim. To determine the clinical and prognostic role of plasma level of stimulating growth factor inmiscellaneouscardiovascular pathology.
Material and Methods. There was carried out a review of literature highlighting the clinical and prognostic role of the plasma level of the stimulating growth factor in cardiovascular pathology.
Results and Discussion. Data from modern literature indicate that recent studies of various non-invasive biomarkers such as troponin I, natriuretic peptide, galectin-3, and stimulating growth factor expressed by gene 2 (ST2) are studied in great detail. ST2 is one of the main biomarkers, which signals the presence and severity of structural remodeling of the heart, especially in patients with acute myocardial infarction and heart failure. It is proved that ST2 possesses a wide range of biological effects, in particular, it plays an important role in the pathogenetic mechanisms of development of cardiovascular diseases. This biomarker is a powerful predictor of development of various cardiovascular diseases and has all the features to recommend determining itfor predicting cardiovascular disease in patients with no clinically significant symptoms.
Conclusion. ST2 is a new biomarker that has proven to bea highly informative prognostic factor in patients with acute and chronic heart failure and coronary artery disease, including STEMI and NSTEMI. In the future, the widespread use of plasma level ST2 will allow predicting the development of various cardiovascular complications and death with high probability. The use of this biomarkerprovides a perspective for the development of preventive measures aimed at improving the quality of life of patients and reducing cardiovascular mortality, as well as loweringthe cost of treatment for cardiovascular diseases. |
|---|